Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma - PubMed (original) (raw)

Clinical Trial

. 2008 Dec;16(12):2022-9.

doi: 10.1038/mt.2008.196. Epub 2008 Sep 16.

Jianda Yuan, Sarah Powel, Humilidad F Gallardo, Teresa S Rasalan, Christina Gonzalez, Gregor Manukian, Jian Wang, Yan Zhang, Paul B Chapman, Susan E Krown, Philip O Livingston, Samuel Ejadi, Katherine S Panageas, Manuel E Engelhorn, Stephanie L Terzulli, Alan N Houghton, Jedd D Wolchok

Affiliations

Clinical Trial

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma

Miguel-Angel Perales et al. Mol Ther. 2008 Dec.

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances immune responses by inducing proliferation, maturation, and migration of dendritic cells (DCs) as well as expansion and differentiation of B and T lymphocytes. The potency of DNA vaccines can be enhanced by the addition of DNA encoding cytokines, acting as molecular adjuvants. We conducted a phase I/II trial of human GM-CSF DNA in conjunction with a multipeptide vaccine (gp100 and tyrosinase) in stage III/IV melanoma patients. Nineteen human leukocyte antigen (HLA)-A*0201+ patients were treated. Three dose levels were studied: 100, 400, and 800 microg DNA/injection, administered subcutaneously every month with 500 microg of each peptide. In the dose-ranging study, three patients were treated at each dose level. The remaining patients were then treated at the highest dose. Most toxicities were grade 1 injection-site reactions. Eight patients (42%) developed CD8+ T-cell responses, defined by a > or =3 SD increase in baseline reactivity to tyrosinase or gp100 peptide in tetramer or intracellular cytokine staining (ICS) assays. There was no relationship between dose and T-cell response. Responding T cells had an effector memory cell phenotype. Polyfunctional T cells were also demonstrated. At a median of 31 months follow-up, median survival has not been reached. Human GM-CSF DNA was found to be a safe adjuvant.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Immunization with GM-CSF DNA followed by tyrosinase and gp100 peptides induced peptide-specific CD8+ T cells assessed by tetramer binding and IFNγ production

PBMCs were collected pre-vaccination, and at several time points during or after vaccination (C = week 7, D = week 11, and E = week 17) and analyzed by tetramer and ICS IFNγ assays. (a) Two patients with positive tetramer assays – patient # 4, Tyrosinase time points D and E; patient # 20 gp100 time point D, and (b) the corresponding ICS IFNγ assays are shown. Only patient # 20 – time points C and D – are positive. Pre-vac, pre-vaccination.

Figure 2

Figure 2. GP100 tetramer-reactive CD8+ cells in the responder population have an effector memory phenotype

PBMCs were analyzed by tetramer assay after in vitro culture using gp100209-217 ITDQVPFSV peptide. (a) Dot plots from patient # 20 at time point D are shown. (b) Contour plots from patient # 20 at time point D show CD3+CD8+ T cells analyzed for tetramer reactivity. Upper plots gated CD3+CD8+tetramer+ T cells; lower row plots gated on CD3+CD8+tetramer-T cells.

Figure 3

Figure 3. Phenotypic characterization of cells secreting IFNγ in ICS assays

ICS assays were performed with CD45RO, CD62L, CD127, CD107a, and granzyme B. (a) Representative dot plots from patient # 20 at time point D are shown. (b) Contour plots from patient # 20 at time point D show the gated CD3+CD8+IFN-γ+ T cells. Upper plots gated on CD3+CD8+IFNγ+ T cells; lower row plots gated on CD3+CD8+IFNγ- T cells.

Figure 4

Figure 4. Polyfunctional antigen specific CD8+ T cells are induced following immunization

(a) Representative dot-plots from sample patient #12 at time point C. Single function gates were set based on negative control (unstimulated sample, bottom row) and were placed consistently across samples. (b) Responses in patient #12 are shown at all 5 time points. Every possible combination of responses is shown on the x axis. Responses are grouped and color coded according to the number of functions. Bars indicate the percentage of the total response contributed by CD8+ T cells with a given functional response. (c) Each pie represents a time point in patient #12 and each slice of the pie represents the fraction of the total response that consists of CD8+ T cells positive for a given number functions.

Similar articles

Cited by

References

    1. Chang DZ, Lomazow W, Joy Somberg C, Stan R, Perales MA. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology. 2004;9:207–215. - PubMed
    1. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:3539–3543. - PMC - PubMed
    1. Kielian T, Nagai E, Ikubo A, Rasmussen CA, Suzuki T. Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1alpha and accumulation of dendritic cells at vaccination sites in vivo. Cancer Immunol Immunother. 1999;48:123–131. - PMC - PubMed
    1. Shinohara H, Yano S, Bucana CD, Fidler IJ. Induction of chemokine secretion and enhancement of contact-dependent macrophage cytotoxicity by engineered expression of granulocyte-macrophage colony-stimulating factor in human colon cancer cells. J Immunol. 2000;164:2728–2737. - PubMed
    1. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. Journal of Urology. 1994;151:622–628. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources